Prothena Corporation plc has released a presentation detailing its ongoing efforts in developing life-saving therapies targeting diseases of protein dysregulation such as Alzheimer's disease, Parkinson's disease, and Transthyretin amyloidosis. The presentation highlights the significant global impact of these conditions, with over 80 million people worldwide living with early symptomatic Alzheimer's and more than 10 million affected by Parkinson's disease. Prothena's strategic collaborations with companies like Bristol Myers Squibb, Novo Nordisk, and Roche are underscored, as well as its various clinical programs, including one partnered Phase 3 program and multiple Phase 1 and 2 programs. The company emphasizes its expert epitope mapping and disease-driven antibody engineering to target proteins with the greatest effect on disease. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。